Shanghai Pharmaceutical (Hunan) Co., Ltd. entered into an agreement to acquire 51% stake in Hunan Runji Pharmaceutical Co., Ltd. from Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) for CNY 149 million on January 16, 2023. The board of directors of Realcan Pharmaceutical Group approved the transaction. Hunan Runji Pharmaceutical recorded total assets of CNY 812.75 million and net assets of CNY 185.94 million as of September 30, 2022.